1 Article

Tailoring Glioblastoma Treatment for Frail Populations: Insights from Genomic and Clinical Data

4 Masab Mansoor^{1*}, Andrew Ibrahim², and Kashif Ansari³

5 ¹ Edward Via College of Osteopathic Medicine; <u>mmansoor@vcom.edu</u> 6 7 ² Texas Tech University Health Science Center; and rew. Ibrahim@ttuhsc.edu ³ East Houston Medical Center, Department of Oncology; kansari@ehoftexas.com 8 9 * Correspondence: mmansoor@vcom.edu 10 Simple Summary: Glioblastoma is an aggressive brain cancer that disproportionately affects older 11 adults, a group often excluded from clinical trials. This study aims to examine how treatment 12 approaches, such as radiation therapy and tumor characteristics, influence survival outcomes in 13 glioblastoma patients aged 65 and older. By analyzing clinical and genomic data, we hope to 14 identify factors that may improve treatment strategies and outcomes for this vulnerable 15 population. Our findings could help guide healthcare professionals in making more personalized 16 and effective treatment decisions for older patients, potentially improving their quality of life and 17 survival. 18 Abstract: Background/Objectives: Glioblastoma is the most common primary malignant brain 19 tumor in adults, with a particularly high incidence among individuals aged 65 and older. Older 20 patients often experience worse outcomes due to limited treatment options, comorbidities, and 21 frailty. This study investigates the impact of radiation therapy and genomic factors on survival 22 outcomes in older glioblastoma patients, aiming to inform treatment strategies for this vulnerable 23 population. Methods: We analyzed clinical and genomic data from 109 glioblastoma patients aged 24 65 and older, obtained from The Cancer Genome Atlas (TCGA). Kaplan-Meier survival analysis 25 was performed to assess the impact of radiation therapy on survival. Correlations between 26 genomic features, including mutation count, tumor mutational burden, and aneuploidy score, and 27 overall survival were examined. Descriptive statistics were used to summarize patient 28 demographics and treatment patterns. Results: Radiation therapy was associated with a higher 29 mean survival (10.3 months) compared to patients who did not receive radiation (6.2 months). 30 Genomic factors, such as mutation count and tumor mutational burden, showed weak negative 31 correlations with survival. Despite the overall poor prognosis, radiation therapy appeared to 32 modestly improve survival in this cohort. Conclusions: Our findings highlight the potential 33 benefits of radiation therapy for older glioblastoma patients, even in the context of frailty and 34 comorbidities. Further research is needed to explore how genomic markers can inform 35 personalized treatment strategies and improve outcomes in this population. 36

39

37

38

Keywords: glioblastoma; geriatric oncology; radiation therapy

40	1. Introduction
41	Glioblastoma (GBM) stands as the most prevalent and aggressive primary
42	malignant brain tumor in adults, with a median survival of approximately 12 to 15
43	months despite intensive treatment efforts [1]. The incidence of GBM notably increases
44	with age, particularly affecting individuals over 65 years. This demographic shift is
45	significant, as the aging population is expanding globally, leading to a higher prevalence
46	of GBM among the elderly. Treating GBM in older adults presents unique
47	challenges. Factors such as decreased functional status, comorbidities, and increased
48	susceptibility to treatment-related toxicities often result in less aggressive therapeutic
49	approaches for this group [2]. Consequently, survival outcomes in elderly patients are
50	generally poorer compared to their younger counterparts [3].
51	Radiation therapy remains a cornerstone in GBM management [4,5]. However, its
52	efficacy and tolerability in the elderly population are subjects of ongoing debate
53	[6]. Some studies suggest that hypofractionated radiation therapy, which delivers higher
54	doses over fewer sessions, may offer comparable survival benefits with reduced side
55	effects. Yet, the optimal radiation regimen for older patients continues to be a matter of
56	investigation [7]. In addition to treatment modalities, genomic factors such as mutation
57	count and tumor mutational burden (TMB) have emerged as potential prognostic
58	indicators in GBM [8]. Understanding the relationship between these molecular
59	characteristics and patient outcomes could pave the way for personalized treatment
60	strategies, particularly in the context of an aging patient population [9].
61	This study aims to evaluate the impact of radiation therapy and specific genomic
62	features on survival outcomes in GBM patients aged 65 and older. By analyzing clinical
63	and molecular data, we seek to identify factors that could inform tailored therapeutic
64	approaches, ultimately improving the prognosis and quality of life for this vulnerable
65	population.
66	2. Materials and Methods
67	2.1. Study Design and Data Source
68	This retrospective cohort study analyzed clinical and genomic data from The Cancer
69	Genome Atlas (TCGA) Glioblastoma Multiforme (GBM) dataset. The dataset was
70	accessed via cBioPortal and included 109 patients aged 65 and older [10-12]. The study
71	complied with TCGA data usage policies.
72	2.2. Patient Selection
73	Patients with a confirmed diagnosis of glioblastoma and available clinical and genomic
74	data were included. Exclusion criteria included incomplete survival data or age below
75	65 years.
76	2.3. Clinical Variables
77	Clinical data included age at diagnosis, sex, overall survival (months), and radiation
78	therapy status (Yes/No). Radiation therapy information was extracted to analyze its
79	association with survival outcomes.
80	2.4. Genomic Analysis
81	

82 83 84	Key genomic variables analyzed included mutation count, tumor mutational burden (TMB), aneuploidy score, and fraction genome altered. These variables were correlated with overall survival to identify potential prognostic markers.
85	2.5. Statistical Analysis
86 87 88 89	Kaplan-Meier survival analysis was used to evaluate the impact of radiation therapy on overall survival. Correlations between genomic variables and survival were assessed using Pearson's correlation coefficient. Descriptive statistics were calculated for demographic and clinical characteristics.
90	2.6. Ethical Considerations
91 92	This study utilized publicly available de-identified data and did not require additional ethical approval. Data were handled in compliance with TCGA policies.
93	2.7. Data Availability
94 95	The dataset used in this study is publicly available through cBioPortal (https://www.cbioportal.org/). No new datasets were generated during this study.
96	3. Results
97 98 99	This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation, as well as the experimental conclusions that can be drawn.
100	3.1. Patient Characteristics
101 102 103	 The study cohort included 109 patients aged 65 and older, with a mean diagnosis age of 73 years (range: 65–89). Males comprised 57% of the cohort, while 43% were female.
104 105	• Radiation therapy was administered to 64% of patients, while the remaining 36% did not receive radiation.
106	3.2. Survival Outcomes
107 108	• Patients receiving radiation therapy demonstrated a mean overall survival of 10.3 months compared to 6.2 months in those who did not receive radiation (Figure 1).
	Kaplan-Meier Survival Curves: Radiation vs. No Radiation
	1.0 Radiation Therapy: Yes Radiation Therapy: No
	tilitadia provide a second provide a sec

0.2

0.0

2.5

5.0

7.5

10.0 Time (Months) Figure 1. Kaplan-Meier Survival Curve. Kaplan-Meier survival curves comparing overall survival in glioblastoma patients aged 65 and older based on radiation

12.5

15.0

17.5

20.0

- 111
- 112
- 113
- 114
- 115
- 115

therapy status. Patients receiving radiation therapy exhibited a higher survival probability over time compared to those who did not receive radiation therapy.

- Kaplan-Meier survival analysis revealed a statistically significant improvement in survival associated with radiation therapy (p < 0.05).
- 3.3. Genomic Correlates of Survival


survival.

Tumor mutational burden (TMB): r = -0.11

An euploidy score: r = -0.03

3.4. Genomic Correlates of Survival

Fraction genome altered: r = -0.07



117

118 119

119

120

122

123 124

125

126

127 128

129

131

130

132 133

134

135

136 137

140

141 142

143

138 139

tolerability [15,16].

4. Discussion This study highlights the importance of tailoring treatment approaches for glioblastoma (GBM) in older adults. Our findings demonstrate that radiation therapy provides a survival benefit for patients aged 65 and older, even in the context of advanced age and potential frailty. These results align with previous studies

Males demonstrated a slightly higher mean survival (8.5 months) compared to

Patients with a high mutation count (≥65 mutations) exhibited a mean survival of

females (7.8 months), though this difference was not statistically significant.

7.5 months compared to 9.0 months in those with lower mutation counts.

Figure 2. Correlation of Mutation Count with Overall Survival. Scatter plot

illustrating the relationship between mutation count and overall survival in

glioblastoma patients aged 65 and older. The weak negative correlation (r = -0.11) suggests that higher mutation counts may be associated with slightly reduced

emphasizing the role of radiation therapy in improving outcomes for elderly GBM patients [13,14]. The observed survival benefit with radiation therapy underscores the need for careful consideration of treatment regimens in this population. While hypofractionated radiation protocols have been suggested as an effective alternative to standard regimens, further studies are needed to identify the optimal approach that balances efficacy and

> Our analysis of genomic factors revealed weak negative correlations between mutation count, tumor mutational burden (TMB), and survival. These findings are consistent with previous studies indicating that high mutation burdens may reflect tumor aggressiveness rather than therapeutic responsiveness [17]. However, key prognostic markers such as IDH1 mutations and MGMT promoter methylation, which are associated with improved survival, were not available in this dataset [18]. Future studies should incorporate these molecular markers to better stratify risk and inform treatment decisions.

> The limitations of this study include its retrospective design and reliance on publicly available data, which may not capture all relevant clinical variables, such as performance status or comorbidities. Additionally, the relatively small sample size limits the generalizability of our findings. Prospective studies with larger cohorts are warranted to validate these results and explore additional factors influencing survival in elderly GBM patients.

5. Conclusions

This study emphasizes the importance of radiation therapy in extending survival for older glioblastoma (GBM) patients, even in the context of advanced age and frailty. While our findings suggest a modest survival benefit from radiation therapy, the weak correlations between genomic factors and survival highlight the complexity of GBM biology in elderly populations.

Further research is needed to integrate clinical and genomic data into personalized treatment strategies, particularly for frail patients who may be unable to tolerate aggressive therapies. Expanding prospective studies and incorporating emerging molecular markers will be critical in improving outcomes for this vulnerable group.

- Author Contributions: Both authors contributed equally to this research.
- 170 **Funding**: This research received no external funding.
- 171Institutional Review Board Statement: Ethical review and approval were waived for this study172due to only using retrospective, publicly available, deidentified data.
- 173Informed Consent Statement: Patient consent was waived because this research solely uses174retrospective, publicly available, deidentified data.175Data Availability Statement: Data obtained from https://www.cbioportal.org.
- 176 **Conflicts of Interest**: The authors declare no conflicts of interest.
- 177 References

144

145 146

147

148

149

150

151

152

153 154

155 156

157

158 159

160

161 162

163 164

165

166 167

168 169

- Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. *CIA*. 2014;9:357-367.
 doi:10.2147/CIA.S44259
- Ladomersky E, Scholtens DM, Kocherginsky M, et al. The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma. *Front Pharmacol.* 2019;10. doi:10.3389/fphar.2019.00200
- Laperriere N, Weller M, Stupp R, et al. Optimal management of elderly patients with glioblastoma. *Cancer Treatment Reviews*.
 2013;39(4):350-357. doi:10.1016/j.ctrv.2012.05.008
- Desideri I, Nardone V, Morelli I, Gagliardi F, Minniti G. Radiation Oncology in Glioblastoma (GBM). In: Lopci E, Mansi L, eds. *Advanced Imaging and Therapy in Neuro-Oncology*. Springer Nature Switzerland; 2024:101-136. doi:10.1007/978-3-031-59341-3 7
- 187 5. Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. *J Neurooncol.* 2017;134(3):479-485.
 188 doi:10.1007/s11060-016-2348-x
- Hau E, Shen H, Clark C, Graham PH, Koh ES, L. McDonald K. The evolving roles and controversies of radiotherapy in the treatment of glioblastoma. *Journal of Medical Radiation Sciences*. 2016;63(2):114-123. doi:10.1002/jmrs.149
- 1917.Managementofglioblastomainolderadults-UpToDate.AccessedJanuary22,2025.192https://www.uptodate.com/contents/management-of-glioblastoma-in-older-adults?utm_source=chatgpt.com
- 193 8. Wang L, Ge J, Lan Y, et al. Tumor mutational burden is associated with poor outcomes in diffuse glioma. *BMC Cancer*.
 194 2020;20(1):213. doi:10.1186/s12885-020-6658-1
- 195 9. Hwang M, Jiang Y. Personalization in digital health interventions for older adults with cancer: A scoping review. *Journal of Geriatric Oncology*. 2023;14(8):101652. doi:10.1016/j.jgo.2023.101652

- 197 10. Cerami et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data.
 198 Cancer Discovery. May 2012 2; 401. <u>PubMed</u>.
- 199 11. Gao et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 200 (2013). PubMed.
- 12. de Bruijn et al. Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE
 Biopharma Collaborative in cBioPortal. Cancer Res (2023). <u>PubMed</u>.
- I3. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. *Cancer.* 2016;122(2):189-197.
 doi:10.1002/cncr.29742
- Yovino S, Grossman SA. Treatment of Glioblastoma in "Elderly" Patients. Curr Treat Options in Oncol. 2011;12(3):253-262.
 doi:10.1007/s11864-011-0158-0
- 15. Kaul D, Florange J, Badakhshi H, et al. Accelerated hyperfractionation plus temozolomide in glioblastoma. *Radiat Oncol.* 2016;11(1):70. doi:10.1186/s13014-016-0645-3
- Yu VY, Nguyen D, O'Connor D, et al. Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics. *PLOS ONE*.
 2021;16(2):e0245676. doi:10.1371/journal.pone.0245676
- I7. Jang B, Yoon D, Lee JY, et al. Integrative multi-omics characterization reveals sex differences in glioblastoma. *Biol Sex Differ*.
 2024;15(1):23. doi:10.1186/s13293-024-00601-7
- 18. Mansouri A, Hachem LD, Mansouri S, et al. MGMT promoter methylation status testing to guide therapy for glioblastoma:
 refining the approach based on emerging evidence and current challenges. *Neuro Oncol.* 2019;21(2):167-178.
 doi:10.1093/neuonc/nov132
- 217 218